Navigation Links
Soligenix Announces 1 for 20 Reverse-Split of its Common Stock
Date:1/31/2012

PRINCETON, N.J., Jan. 31, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to implement a one-for-twenty reverse split of its common stock which will take effect tomorrow morning.

"Given our current stock price, we believe this is an opportune time to effect a reverse stock split," stated Christopher J. Schaber, PhD, President and CEO of Soligenix. "We believe the reverse split improves Soligenix's capital structure and creates a more appealing stock price, thereby, giving us access to a larger market audience for our common stock. Importantly, it also facilitates easier trading of our stock in light of the new low-price stock trading limitations being imposed by a number of prominent clearing firms. After a relatively quiet period following the termination of our Phase 3 clinical trial of orBec® in acute GI GVHD, we expect to be announcing developments in the coming weeks with our other novel programs, namely, thermostability, acute radiation syndrome, and acute radiation enteritis."

The reverse split will become effective at 9:00 AM EST on Wednesday, February 1, 2012. The reverse split, which was overwhelmingly approved by the Company's stockholders on September 23, 2010 and recently unanimously authorized by its Board, will reduce the number of shares of the Company's outstanding common stock from approximately 221 million to approximately 11 million and proportionately reduce the number of authorized shares of the Company's capital stock. The reverse split will not affect any stockholder's ownership percentage of Soligenix's shares. The reverse split will not change the par value of the common stock or the number of shares of common stock Soligenix is authorized to issue.

The split-adjusted shares of Soligenix's common stock will begin trading on
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
2. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
3. Soligenix to Present at 8th Annual BIO Investor Forum
4. Soligenix to Present at 12th Annual BIO CEO & Investor Conference
5. Soligenix Reports Third Quarter 2009 Financial Results
6. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
7. Soligenix Announces Completion of Patient Enrollment in Phase 2 Acute GVHD Prevention Clinical Trial
8. Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments
9. Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate
10. Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors
11. Soligenix Reports Second Quarter 2010 Financial Results and Reviews Accomplishments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Follow us on LinkedIn –Cholesterol ... cholesterol carrier or lipoprotein in the blood. Such tests ... in the body, especially along the walls of blood ... other cardiovascular disorders. Cardiovascular Diseases (CVD) is the leading ... on a regular basis, to assess an individual’s risk ...
(Date:9/30/2014)... 2014 CORD:USE Cord Blood Bank – ... has entered into an Equity and Exclusive Services Agreement ... series of patented technologies for the isolation of human ... Tianhe is performing Phase I/II clinical trials in ... using Tianhe,s Stem Cell Educator Therapy showing that ...
(Date:9/30/2014)... Switzerland (PRWEB) September 30, 2014 ... software solutions for drug discovery and related ... FUNGITECT consortium has chosen Genedata Selector as ... sequencing (NGS) data. FUNGITECT is a European ... invasive fungal diseases via individualized anti-fungal drug ...
(Date:9/30/2014)...  KemPharm, Inc., a clinical-stage specialty pharmaceutical company ... new molecular entity (NME) prodrugs, announced today that ... issued U.S. Patent No. 8,816,083 to KemPharm for ... Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydromorphone, ... The patent, which extends through 2032, provides ...
Breaking Biology Technology:Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... — Just in case anyone doubts that the Wisconsin Alumni ... defend its stem cell patent, Andy Cohn would like to ... manager for WARF, said the foundation, armed with a $1.5 ... to its controversial stem cell patent. , ,In the wake ...
... had the opportunity to watch lots of little companies become ... a company is no less awkward than a child's trip ... big without really growing up. , ,Fortunately, that isn't ... the social media market. Over the last year, the company ...
... Joint Legislative Audit Committee voted unanimously to authorize an ... agencies. , ,The 6-0 vote came after several hours ... personnel confirmed the state has lost millions of dollars ... several agencies have been plagued by varying problems, including ...
Cached Biology Technology:WARF says it's ready for a legal challenge on stem cells 2WARF says it's ready for a legal challenge on stem cells 3WARF says it's ready for a legal challenge on stem cells 4Six Apart grows up 2Six Apart grows up 3Audit of multi-million dollar state IT spending will proceed 2
(Date:9/30/2014)... most comprehensive assessment conducted by the Ocean Health ... of 100 in overall health. In addition, for ... and the 15 ocean regions beyond national jurisdiction ... a healthy climate, safeguarding biodiversity and providing sustainable ... of the index, a partnership led by scientists ...
(Date:9/30/2014)... led by Clemson University associate professor Brian Powell, ... the U.S. Department of Energy,s Experimental Program to ... impact on South Carolina in the advancement of ... "Understanding the scientific and engineering needs for safely ... technologies is imperative if South Carolina is to ...
(Date:9/30/2014)... -- Pollution in urban and farm runoff in Hawaii ... study finds. , The study, published Tuesday in ... nitrogen in the runoff ends up in algae that ... the animals, eyes, flippers and internal organs. , Scientists ... National Oceanic and Atmospheric Administration (NOAA) conducted the study ...
Breaking Biology News(10 mins):Rating the planet's oceans 2Rating the planet's oceans 3Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3
... evidence a chemical referred to as hexavalent chromium, or ... is consumed in drinking water. The two-year study ... animals given hexavalent chromium developed malignant tumors. , ... cancer in humans in certain occupational settings as a ...
... has examined the mechanisms behind latent cell memory, which ... suddenly to appear. Special yeast cells for example, can ... hermaphrodite. , Researchers from the Niels Bohr Institute ... and computer simulations to examine fundamental mechanisms of cell ...
... international journal, the British Journal of Obstetrics and Gynaecology, ... increases in clinical reasons for caesareans such as complications ... to societal factors. , The research project looked at ... (more than 430,000 births) and analysed the ...
Cached Biology News:Hexavalent chromium in drinking water causes cancer in lab animals 2Latent memory of cells comes to life 2Latent memory of cells comes to life 3Study shows dramatic increase in Caesarean sections 2
MOUSE ANTI BOVINE TROPONIN I...
Ready-to-use; 40mg/ml X-Gal and 32mg/ml IPTG...
Normal donkey serum collected from healthy normal donkeys....
This BioSolution package is excellent for doing fluorescence thermal melt experiments on nucleic acids, studies involving biomolecular interactions, protein folding experiments, and more!...
Biology Products: